Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 4

1(20.0%)

5Total

N/A(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07539129Not ApplicableNot Yet Recruiting

Investigating the Efficacy of Oral Probiotics Versus Placebo in Pakistani Patients With Moderate Acne on Acne Lesion Count and Systemic Inflammation

Role: collaborator

NCT07519174Not ApplicableNot Yet Recruiting

A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks

Role: collaborator

NCT07485777Not ApplicableNot Yet Recruiting

Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Women With Melasma

Role: collaborator

NCT07273851Not ApplicableCompleted

Comparison of Propofol and Ketofol as Induction Agents for Electroconvulsive Therapy

Role: lead

NCT02731560Phase 4Completed

Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)

Role: collaborator

All 5 trials loaded